Association of CYP2C9*2 With Bosentan-Induced Liver Injury
- 17 July 2013
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 94 (6) , 678-686
Abstract
Bosentan (Tracleer) is an endothelin receptor antagonist prescribed for the treatment of pulmonary arterial hypertension (PAH). Its use is limited by drug‐induced liver injury (DILI). To identify gen...Keywords
This publication has 50 references indexed in Scilit:
- Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitroEuropean Journal of Pharmacology, 2013
- Functional characterization of ABCC2 promoter polymorphisms and allele-specific expressionThe Pharmacogenomics Journal, 2012
- Investigation of the CYP2C9 Induction Profile in Human Hepatocytes by Combining Experimental and Modelling ApproachesCurrent Drug Metabolism, 2009
- Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancyGut, 2008
- Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinololPharmacogenetics and Genomics, 2008
- Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and SildenafilDrug Metabolism and Disposition, 2007
- Results of European post-marketing surveillance of bosentan in pulmonary hypertensionEuropean Respiratory Journal, 2007
- Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 GenotypesGastroenterology, 2007
- Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2Pharmaceutical Research, 2004
- Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1995